← feed

Is NCT03292185 results overdue?

Yes — results are overdue. Primary completion was 2018-01-02; the FDAAA-801 reporting deadline (2019-01-02) passed 2727 days ago and no results are posted on ClinicalTrials.gov.

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

NCT IDNCT03292185 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-01-02 (ACTUAL)
Reporting deadline2019-01-02 (completion + 365d)
Days overdue2727
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 7b75fcf74e87e0c9… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03292185. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →